LAVA Therapeutics NV (LVTX) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Dilution Analysis

Low Risk

Limited dilution potential

Last updated: November 06, 2025

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 0.24% (2 years)

Historical Dilution Factor: minimal recent dilution

Outstanding Shares

27M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

LVTX currently has 26.9M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 0.24% over the past 2 years.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding
Nov 06, 2025	10-Q filing \| 26.9M shares outstanding	27M
Aug 13, 2025	10-Q filing \| 26.9M shares outstanding	27M
May 14, 2025	10-Q filing \| 26.9M shares outstanding	27M
Mar 28, 2025	10-K filing \| 26.8M shares outstanding	27M
Mar 20, 2024	20-F filing \| 26.3M shares outstanding	26M
Apr 11, 2023	20-F filing \| 26.3M shares outstanding	26M
Apr 12, 2022	F-3 filing: The company is filing an F-3 form to register a shelf offering of common shares and debt securities, with a total proposed amount of $250,000,000.	26M
Mar 24, 2022	20-F filing \| 25.8M shares outstanding	26M
Mar 02, 2021	F-1 filing: The F-1 filing outlines estimated expenses related to the offering, including SEC registration fees, FINRA filing fees, Nasdaq Global Market listing fees, printing and engraving expenses, legal fees, accounting fees, and miscellaneous costs.	N/A

Back to LVTX Details